New Phase 3 trials registered, week of October 26, 2026: 4 industry trials
Industry sponsors registered 4 Phase 3 trials on ClinicalTrials.gov so far in the week of October 26 to November 1, 2026. They plan to enroll 1,424 participants in all; the largest, Jiangsu HengRui Medicine's HRS-6209 + Letrozole trial, plans to enroll 1,050.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, November 1, 2026.
The trials
- Jiangsu HengRui registers Phase III trial of HRS-6209 plus letrozole in advanced breast cancer. Sponsor: Jiangsu HengRui Medicine Co., Ltd. Condition: Breast Cancer. Interventions: HRS-6209 + Letrozole, Dalpciclib/Palbociclib + Letrozole/Anastrozole. Phase: Phase 3. Planned enrollment: 1,050. Planned primary completion: July 2031. First posted October 26, 2026. Record: NCT07894328.
- Amneal Pharmaceuticals registers Phase 3 trial of testosterone cypionate auto-injector. Sponsor: Amneal Pharmaceuticals, LLC. Condition: Male Hypogonadism. Interventions: Testosterone Cypionate 75 mg, Testosterone cypionate 50 mg, Testosterone cypionate 100 mg. Phase: Phase 3. Planned enrollment: 190. Planned primary completion: March 2027. First posted October 27, 2026. Record: NCT07898072.
- AbbVie registers Phase 3 trial of upadacitinib in pediatric non-segmental vitiligo. Sponsor: AbbVie. Condition: Non-Segmental Vitiligo. Intervention: Upadacitinib. Phase: Phase 3. Planned enrollment: 154. Planned primary completion: August 2032. First posted October 27, 2026. Record: NCT07896434 (Ph3 Peds Viti).
- Swedish Orphan Biovitrum registers Phase 3 trial of pegcetacoplan in kidney transplant recipients. Sponsor: Swedish Orphan Biovitrum. Conditions: C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative, Glomerulonephritis (IC-MPGN), Kidney Transplantation, Recurrent Glomerular Disease After Kidney Transplantation. Intervention: Pegcetacoplan. Phase: Phase 3. Planned enrollment: 30. Planned primary completion: January 2031. First posted October 27, 2026. Record: NCT07898774 (PRESERVE).
By the numbers
- Trials: 4, from 4 lead sponsors.
- Planned enrollment: 1,424 in all across 4 trials; median 172 per trial.
- Largest: Jiangsu HengRui Medicine's HRS-6209 + Letrozole trial, 1,050. Smallest: Swedish Orphan Biovitrum's PRESERVE trial, 30.
- Phases as registered: 4 Phase 3.
- Planned primary completion: from March 2027 to August 2032.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.